The measurement of HIV-1 viral load in resource-limited settings: How and where?

Clinical Laboratory

Volumn 53, Issue 3-4, 2007, Pages 135-148

  Rouet, Francois ^a   Rouzioux, Christine ^b  

^a CENTRE MURAZ   (Burkina Faso)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Alternative methods; HIV 1 viral load; p24 antigen; PCR; Resource limited settings; Reverse transcriptase

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; EFAVIRENZ; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

CORRELATION FUNCTION; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG MONITORING; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; EARLY DIAGNOSIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC VARIABILITY; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOASSAY; INTERMETHOD COMPARISON; NONHUMAN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REBOUND; REPRODUCIBILITY; RESOURCE ALLOCATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; VIRUS GENE; VIRUS LOAD; VIRUS RESISTANCE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPING COUNTRIES; GENES, GAG; GENES, POL; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; REAGENT KITS, DIAGNOSTIC; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; TERMINAL REPEAT SEQUENCES; VARIATION (GENETICS); VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34247514336     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, Rubin M, Simberkoff MS, Hamilton JD, and the Veterans Affairs Cooperative Study Group on AIDS. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996, 334:426-431.
2. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 1997, 126:939-945.
3. Mellors JW, A. M, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saab AJ, Detels R, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
4. Lambert JS, Harris DR, Stiehm ER, Moye J, Fowler MG, Meyer III WA, Bethel J, Mofenson LM. Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection. J Acquir Immune Defic Syndr 2003, 34:512-519.
5. Akileswaran C, Lurie MN, Flanigan TP, Mayer KH. Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis 2005, 41:376-385.
6. Dabis F. Children and HIV in Africa: what is next? Lancet 2003, 362:1597-1598.
7. World Health Organization: Scaling up Antiretroviral Therapy in Resource-limited Settings: Guidelines for a Public Health Approach. 2003 revision. Geneva: WHO; December 2003. Available at (accessed November 6, 2004): http://www.who.int/3by5/publications/documents/ arv_guidelines/en/.
8. Panhotra BR, Hassan ZU, Joshi CS, Bahrani A. Visual detection of multiple viral amplicons by dipstick assay: its application in screening of blood donors a welcome tool for the limited resource settings. J Clin Microbiol 2005, 43:6218.
9. Lopes-Campos GH, Garcia-Albert L, Martin-Sanchez F, Garcia-Saiz A. Analysis and management of HIV peptide microarray experiments. Methods Inf Med 2006, 45:158-162.
10. Guttikonda S, Wang W, Suresh M. Molecular zipper assays: a simple homosandwich with the sensitivity of PCR. J Pharm Pharm Sci 2004, 7:7-16.
11. Peter JB, Sevall Sanders J. Molecular-based methods for quantifying HIV viral load. AIDS Patient Care and Stds 2004, 18:75-79.
12. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994, 32:292-300.
13. Brambilla DJ, Granger S, Jennings C, Bremer JW. Multisite comparison of reproducibility and recovery from the standard and ultrasensitive Roche AMPLICOR HIV-1 MONITOR assays. J Clin Microbiol 2001, 39:1121-1123.
14. Van Gemen B, Kievits T, Nara P. Huisman HG, Jurriaans S, Goudsmit J, Lens P. Qualitative and quantitative detection of HIV-1 RNA by nucleic acid sequence-based amplification. AIDS 1993, 7:S107-S110.
15. Zanchetta N, Nardi G, Tocalli L, Drago L, Bossi C, Pulvirenti FR, Galli C, Gismondo MR. Evaluation of the Abbott LCx HIV-1 RNA Quantitative, a new assay for quantitative determination of human immunodeficiency virus type 1 RNA. J Clin Microbiol 2000, 38:3882-3886.
16. Pachl C, Todd JA, Kern DG, Sheridan PJ, Fong SF, Stempien M, Hoo B, Besemer D, Yeghiazarian T, Irvine B, et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA (bDNA) signal amplification assay. J Acquir Immune Defic Syndr 1995, 8:446-454.
17. Revets H, Marissens D, de Wit S, Lacor P, Clumeck N, Lauwers S, Zissis G. Comparative evaluation of NASBA HIV-1 RNA QT, Amplicor-HIV Monitor, and Quantiplex HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 in plasma. J Clin Microbiol 1996, 34:1058-1064.
18. Coste J, Montes B, Reyes J, Peeters M, Segarra C, Vendrell JP, Delaporte E, Segondy M. Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma. J Med Virol 1996, 50:293-302.
19. Chew CB, Herring BL, Zheng F, Browne C, Saksena NK, Cunningham L, Dwyer DE. Comparison of three commercial assays for the quantification of HIV-1 RNA in plasma from individuals infected with different HIV-1 subtypes. J Clin Virol 1999, 14: 87-94.
20. Murphy DG, Cote L, Fauvel M, Rene P, Vincelette J. Multicenter comparison of Roche COBAS AMPLICOR MONITOR version 1.5, Organon Teknika NucliSens QT with extractor, and Bayer Quantiplex version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2000, 38:4034-4041.
21. Anastassopoulou CG, Toulomi G, Katsoulidou A, Hatzitheodoron H, Pappa M, Paraskevis D, Lazanas M, Gargalianos P, Hatzakis A. Comparative evaluation of the QUANTIPLEX HIV-1 RNA 2.0 and 3.0 (BDNA) assays and the AMPLICOR HIV-1 MONITOR v1.5 test for the quantitation of human immunodeficiency virus type 1 RNA in plasma.J Virol Methods 2001, 91:67-74.
22. Swanson P, Soriano V, Devare SG, Hackett J. Comparative performance of three viral load assays on human immunodeficiency virus type 1 (HIV-1) isolates representing group M (subtypes A to G) and group O: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR version 1.5, and Quantiplex HIV-1 RNA version 3.0. J Clin Microbiol 2001, 39:862-870.
23. Elbeik T, Alvord WG, Trichavaroj T, deSouza M, Dewar R, Brown A, Chernoff D, Michael NL, Nassos P, Hadley K, et al. Comparative analysis of HIV-1 viral load assays on subtype quantification: Bayer Versant HIV-1 RNA 3.0 versus Roche Amplicor HIV-1 monitor version 1.5. J Acquir Immune Defic Syndr 2002, 29:330-339.
24. Katsoulidou A, Papachristou E, Petrodaskalaki M, Sypsa V, Anastassopoulou CG, Gargalianos P, Karafoulidou A, Lazanas M, Kordossis T, Andoniadou A, et al. Comparison of three current viral load assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma. J Virol Methods 2004, 121: 93-99.
25. Kumarasamy N, Flanigan TP, Mahajan AP, Carpenter CCJ, Mayer KH, Solomon S. Monitoring HIV treatment in the developing world. Lancet Infect Dis 2002, 2:656-657.
26. Crowe S, Turnbull S, Oelrichs R, Dunne A. Monitoring of human immunodeficiency virus infection in resource-constrained countries. Clin Infect Dis 2003, 37:S25-S35.
27. Majchrowics M. Beyond antiretroviral access: low-cost laboratory tests needed for the developing world. AIDS 2003, 17:S12-S15.
28. Balakrishnan P, Solomon S, Kumarasamy N, Mayer KH. Low-cost monitoring of HIV infected individuals on highly active antiretroviral therapy (HAART) in developing countries. Indian J Med Res 2005, 121:345-355.
29. UNICEF. Monitoring and statistics. http://www.unicef.org/ statistics 2005.
30. Amendola A, Bordi L, Angeletti C, ViscoComandini U, Abbate I, Cappiello G, Budabbus MA, Eljhawi OA, Mehabresh MI, Girardi E, et al. Underevaluation of HIV-1 plasma viral load by a commercially available assay in a cluster of patients infected with HIV-1 A/G circulating recombinant form (CRF02). J Acquir Immune Defic Syndr 2002, 31:488-494.
31. Plantier JC, Gueudin M, Damond T, Braun J, Mauclere P, Simon F. Plasma RNA quantification and HIV-1 divergent strains. J Acquir Immune Defic Syndr 2003, 33:1-7.
32. Swanson P, de Mendoza C, Joshi Y, Golden A, Hodinka RL, Soriano V, Devare SG, Hackett J. Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. J Clin Microbiol 2005, 43:3860-3868.
33. Katsoulidou A, Petrodaskalaki M, Sypsa V, Papachristou E, Anastassopoulou CG, Gargalianos P, Karafoulidou A, Lazanas M, Kordossis T, Andoniadou A, et al. Evaluation of the clinical sensitivity for the quantification of human immunodeficiency virus type 1 RNA in plasma: Comparison of the new COBAS TaqMan HIV-1 with three current HIV-RNA assays - LCx HIV RNA quantitative, VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 Monitor v1.5. J Virol Methods 2006, 131:168-174.
34. Gomes P, Palma AC, Cabanas J, Abecasis A, Carvalho AP, Ziermann R, Diogo I, Goncalves F, Lobo CS, Camacho R. Comparison of the COBAS TAQMANtrade mark HIV-1 HPS with VERSANT HIV-1 RNA 3.0 Assay (bDNA) for plasma RNA quantitation in different HIV-1 subtypes. J Virol Methods 2006, 135:223-228.
35. de Mendoza C, Koppelman M, Montes B, Ferre V, Soriano V, Cuypers H, Segondy M, Oosterlaken T. Multicenter evaluation of the NucliSens EasyQ HIV-1 v1.1 assay for the quantitative detection of HIV-1 RNA in plasma. J Virol Methods 2005, 127: 54-59.
36. Stevens W, Wiggill T, Horsfield P, Coetzee L, Scott LE. Evaluation of the NucliSens EasyQ assay in HIV-1 infected individuals in South Africa. J Virol Methods 2005, 124:105-110.
37. Yao J, Liu Z, Ko LS, Pan G, Jiang Y. Quantitative detection of HIV-1 RNA using NucliSens EasyQ HIV-1 assay. J Virol Methods 2005, 129:40-46.
38. Gottesman BS, Grossman Z, Lorber M, Levi I, Shitrit P, Katzir M, Shahar E, Gottesman C, Chowers M. Comparative performance of the amplicor HIV-1 monitor assay versus NucliSens EasyQ in HIV subtype C-infected patients. J Med Virol 2006, 78:883-887.
39. Swanson P, Huang SH, Holzmayer V, Bodelle P, Yamaguchi J, Brennan C, Badaro R, Brites C, Abravaya K, Devare SG, et al. Performance of the automated Abbott RealTime (TM) HIV-1 assay on a genetically diverse panel of specimens from Brazil. J Virol Methods 2006, 134:237-243.
40. Garcia-Diaz A, Clewley GS, Booth CL, Labett W, McAllister N, Geretti AM. Comparative evaluation of the performance of the Abbott real-time human immunodeficiency virus type I (HIV-1) assay for measurement of HIV-1 plasma viral load following automated specimen preparation. J Clin Microbiol 2006, 44: 1788-1791.
41. Schupbach J, Boni J. Quantitative and sensitive detection of immune-complex-dissociated HIV-1 p24 antigen after boiling. J Virol Methods 1993, 43:247-256.
42. Schupbach J, Boni J, Tomasik Z, Jendis J, Seger R, Kind C. Sensitive detection and early prognostic significance of p24 antigen in heat-denatured plasma of human immunodeficiency virus type 1-infected infants. Swiss Neonatal HIV-1 Study Group. J Infect Dis 1994, 170:318-324.
43. Schupbach J, Flepp M, Pontelli D, Tomazik S, Luthi R, Boni J. Heat-mediated immune complex dissociation and enzyme linked immunosorbent assay signal amplification render p24 antigen detection in plasma as sensitive as HIV-1 RNA detection by polymerase chain reaction. AIDS 1996, 10:1085-1090.
44. Lyamuya E, Bredberg-Raden U, Massawe A, Urassa E, Kawo G, Msemo G, Kazimoto T, Ostborn A, Karlsson K, Mhalu F, et al. Performance of a modified HIV-1 p24 antigen assay for early diagnosis of HIV-1 infection in infants and prediction of mother-to-infant. J Acquir Immune Defic Syndr 1996, 12:421-426.
45. Rich KC, Janda W, Kalish LA, Lew J, Hofheinz D, Landesman S, Pitt J, Diaz C, Moye J, Sullivan JL. Immune complex-dissociated p24 antigen in congenital or perinatal HIV infection: role in the diagnosis and assessment of risk of infection in infants. J Acquir Immune Defic Syndr 1997, 15:198-203.
46. Boni J, Opravil O, Tomasik Z, Rothen M, Bisset L, Grob PJ, Luthy R, Schupbach J. Simple monitoring of antiretroviral therapy with a signal-amplification-boosted HIV-1 p24 antigen assay with heat-denatured plasma. AIDS 1997, 11:F47-F52.
47. Nadal D, Böni J, Kind C, Varnier OE, Steiner F, Tomasik Z, Schüpbach J. Prospective evaluation of amplification-boosted ELISA for heat-denatured p24 antigen for diagnosis and monitoring of pediatric human immunodeficiency virus type 1 infection. J Infect Dis 1999, 180:1089-1095.
48. Ledergerber B, Flepp M, Böni J, Tomasik Z, Cone RW, Lüthy R, Schüpbach J. Human immunodeficiency virus type 1 p24 concentration measured by boosted ELISA of heat-denatured plasma correlates with decline in CD4 cells, progression to AIDS, and survival: comparison with viral RNA measurement. J Infect Dis 2000, 181:1280-1287.
49. Bürgisser P, Vernazza P, Flepp M, Böni J, Tomasik Z, Hummel U, Pantaleo G, Schüpbach J, and the Swiss HIV cohort study. Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. J Acquir Immune Defic Syndr 2000, 23:138-144.
50. Schupbach J, Tomasik Z, Nadal D, Ledergerber B, Flepp M, Opravil M, Boni J. Use of HIV-1 p24 as a sensitive, precise and inexpensive marker for infection, disease progression and treatment failure. Int J Antimicrobial Agents 2000, 16:441-445.
51. Guay LA, Hom DL, Kabengera SR, Piwowar-Manning EM, Kataaha P, Ndugwa C, Marum LH, Kalyesubula I, Jackson JB. HIV-1 LCD p24 antigen detection in Ugandan infants: use in early diagnosis of infection and as a marker of disease progression. J Med Virol 2000, 62:426-434.
52. Schupbach J, Boni J, Flepp M, Tomasik Z, Joller H, Opravil M. Antiretroviral treatment monitoring with an improved HIV-1 p24 antigen test: An inexpensive alternative to tests for viral RNA. J Med Virol 2001, 65:225-232.
53. Pascual A, Cachafeiro A, Funk ML, Fiscus SA. Comparison of an assay using signal amplification of the heat- dissociated p24 antigen with the Roche Monitor human immunodeficiency virus RNA assay. J Clin Microbiol 2002, 40:2472-2475.
54. Sterling TR, Hoover DR, Astemborski J, Vlahov D, Bartlett JG, Schupbach J. Heat-denaturated human immunodeficiency virus type 1 protein 24 antigen: prognostic value in adults with early-stage disease. J Infect Dis 2002, 186:1181-1185.
55. Sutthent R, Gaudart N, Chokpaibulkit K, Tanliang N, Kanoksinsombath C, Chaisilwatana P. p24 antigen detection assay modified with a booster step for diagnosis and monitoring of human immunodeficiency virus type 1 infection. J Clin Microbiol 2003, 41:1016-1022.
56. Schupbach J, Boni J, Bisset LR, Tomasik Z, Fischer T, Gunthard HF, Ledergerber B, Opravil T. HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy. J Acquir Immune Defic Syndr 2003, 33:292-299.
57. Ribas SG, Ondoa P, Schupbach J, van der Groen G, Fransen K. Performance of a quantitative human immunodeficiency virus type 1 p24 antigen assay on various HIV-1 subtypes for the follow-up of human immunodeficiency type 1 seropositive individuals. J Virol Methods 2003, 113:29-34.
58. Bonard D, Rouet F, Toni TA, Minga A, Huet C, Ekouevi DK, Dabis F, Salamon R, Rouzioux C. Field evaluation of an improved assay using a heat-dissociated p24 antigen for adults mainly infected with HIV-1 CRF02_AG strains in Cǒte d'Ivoire, West Africa. J Acquir Immune Defic Syndr 2003, 34:267-273.
59. Prado JG, Shintani A, Bofill M, Clotet B, Ruiz L, Marinez Picardo J. Lack of longitudinal intrapatient correlation between p24 antigenemia and levels of HIV-1 RNA in patients with chronic HIV-1 infection during structured treatment interruptions. J Clin Microbiol 2004, 42:1620-1625.
60. Respess RA, Cachafeiro A, Withum D, Fiscus SA, Newman D, Branson B, Varnier OE, Lewis K, Dondero TJ. Evaluation of an ultrasensitive p24 antigen assay as a potential alternative to human immunodeficiency virus type 1 RNA viral load assay in resource-limited settings. J Clin Microbiol 2005, 43:506-508.
61. Lombard JP, Vray M, Kafando A, Lemee V, Ouedraogo-Traore R, Corrigan GE, Plantier JC, Simon F, Braun J. Plasma virion reverse transcriptase activity and heat dissociation-boosted p24 assay for HIV load in Burkina Faso, West Africa. AIDS 2005, 19:1273-1277.
62. Stevens G, Rekhviashvili N, Scott LE, Gonin R, Stevens W. Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. J Clin Microbiol 2005, 43:857-861.
63. Li CC, Seidel KD, Coombs RW, Frenkel LM. Detection and quantification of human immunodeficiency virus type 1 p24 antigen in dried whole blood and plasma on filter paper stored under various conditions. J Clin Microbiol 2005, 43:3901-3905.
64. Kozinetz CA, Matusa R, Ruta S. Hacker CS, Cernescu C, Cazacu A. Alternatives to HIV-RNA and CD4 count to monitor HIV disease progression: A prospective cohort study in Romania. J Med Virol 2005, 77:159-163.
65. Jennings C, Fiscus SA, Crowe SM, Danilovic AD, Morack RJ, Scianna S, Cachafeiro A, Brambilla DJ, Schupbach J, Stevens W, et al. A comparison of human immunodeficiency virus (HIV-1) RNA surrogate assays to the standard HIV-1 RNA assay. J Clin Microbiol 2005, 43:5960-5966.
66. Patton JC, Sherman GG, Coovadia AH, Stevens WS, Meyers TM. Ultrasensitive human immunodeficiency virus type 1 p24 antigen assay modified for use on dried whole-blood spots as a reliable, affordable test for infant diagnosis. Clinical and Vaccine Immunology 2006, 13:152-155.
67. Ondoa P, Dieye TN, Vereecken C, Camara M, Diallo AA, Fransen K, Litzroth A, Mboup S, Kestens L. Evaluation of HIV-1 p24 antigenemia and level of CD8(+)CD38(+) T cells as surrogate markers of HIV-1 RNA viral load in HIV-1-infected patients in Dakar, Senegal. J Acquir Immune Defic Syndr 2006, 41:416-424.
68. Malmsten A, Shao XW, Sjodahl S, Fredriksson EL, Pettersson I, Leitner T, Kallander CFR, Sandstrom E, Gronowitz JS. Improved HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma. J Med Virol 2005, 76:291-296.
69. Braun J, Plantier JC, Hellot MF, Tuaillon E, Gueudin M, Damond F, Malmsten A, Corrigan GE, Simon F. A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes. AIDS 2003, 17:331-336.
70. Malmsten A, Shao XW, Aperia K, Corrigan GE, Sandstrom E, Kallander CFR, Leitner T, Gronowitz JS. HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma. J Med Virol 2003, 71:347-359.
71. Greengrass VL, Turnbull SP, Hocking J, Dunne AL, Tachegjian G, Corrigan GE, Crowe SM. Evaluation of a low cost reverse transcription assay for plasma HIV-1 viral Load monitoring. Current HIV-1 Research 2005, 3:183-190.
72. Sivapalasingam S, Essajee S, Nyambi PN, Itri V, Hanna B, Holzman R, Valentine F. Human immunodeficiency virus (HIV-1) reverse transcriptase activity correlates with HIV-1 RNA load: implications for resource-limited settings. J Clin Microbiol 2005, 43:3793-3796.
73. Seyoum E, Wolday D, Girma M, Malmsten A, Meselle T, Gronowitz JS, Britton S. Reverse transcriptase activity for quantitation of HIV-1 subtype C in plasma: Relation to RNA copy number and CD4 T-cell count. J Med Virol 2006, 78:161-168.
74. Tuaillon E, Gueudin M, Lemee V, Gueit I, Roques P, Corrigan GE, Plantier JC, Simon F, Braun J. Phenotypic susceptibility to non-nucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J Acquir Immune Defic Syndr 2004, 37:1543-1549.
75. Niesters HGM. Quantitation of viral load using real-time amplification techniques. Methods 2001, 25:419-429.
76. Bustin SA, Benes V, Nolan T, Pfaffl MW. Quantitative real-time RT-PCR - a perspective. J Mol Endocrinol 2005, 34:597-601.
77. Wong ML, Medrano JF. Real-time PCR for mRNA quantitation. Biotechniques 2005, 39:75-85.
78. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology 1992, 10:413-417.
79. Lewin SR, Vesanen M, Kostrikis L, Hurley A, Duran M, Zhang L, Ho DD, Markowitz M. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type1 1-infected individuals on prolonged effective antiretroviral therapy. J Virol 1999, 73:6099-6103.
80. Mackay IM, Arden KE, Nitsche A. Real-time PCR in virology. Nucl Acid Res 2002, 30:1292-1305.
81. Mackay IM. Real-time PCR in the microbiology laboratory. Clin Microbiol Infect 2004, 10:190-212.
82. deBaar MP, vanDooren MW, deRooij E, Bakker M, vanGemen B, Goudsmit J, deRonde A. Single rapid real-time monitored isothermal RNA amplification assay for quantification of human immunodeficiency virus type 1 isolates from groups M, N, and O. J Clin Microbiol 2001, 39:1378-1384.
83. Saha BK, Tian BH, Bucy RP. Quantitation of HIV-1 by real-time PCR with a unique fluorogenic probe. J Virol Methods 2001, 93:33-42.
84. deBaar MP, Timmer EC, Bakker M, deRooij E, vanGemen B, Goudsmit J. One-tube real-time isothermal amplification assay to identify and distinguish human immunodeficiency virus type 1 subtypes A, B, and C and circulating recombinant forms AE and AG. J Clin Microbiol 2001, 39:1895-1902.
85. Victoria JG, Lee DJ, McDougall BR, Robinson WEJ. Replication kinetics for divergent type 1 human immunodficiency viruses using quantitative SYBR green I real-time polymerase chain reaction. Aids Res Hum Retrovirus 2003, 19:865-874.
86. Gibellini D, Vitone F, Gori E, La Place M, Re MC. Quantitative detection of human immunodeficiency virus type 1 (HIV-1) viral load by SYBR green real-time RT-PCR technique in HIV-1 seropositive patients. J Virol Methods 2004, 115:183-189.
87. Candotti D, Temple J, Owusu Ofori S, Allain JP. Multiplex real-time quantitative RT-PCR assay for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1. J Virol Methods 2004, 118:39-47.
88. Rouet F, Ekouevi DK, Chaix ML, Burgard M, Inwoley A, Tony TD, Danel C, Anglaret X, Leroy V, Msellati F, et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol 2005, 43:2709-2717.
89. Ayele W, de Baar MP, Goudsmit J, Kliphuis A, Tilahun T, Dorigo Zetsma W, Wolday D, Abebe A, Mengistu Y, Pollakis G. Surveillance technology for HIV-1 subtype C in Ethiopia: An env-based NASBA molecular beacon assay to discriminate between subcluster C and C′. J Virol Methods 2005, 130:22-29.
90. Shapshak P, Duncan R, McCoy CB, Page JB. Quantification of HIV gag RNA using real time reverse transcriptase PCR. Front Biosci 2005, 10:135-142.
91. Watanaveeradej V, Sirirattanaphoomee S, Chantratita W, Nitayaphan S, Viputtikul K, Kerdpanich A, Samakoses R, Simasathien S. Quantification of HIV-1 RNA load by one-tube-one-step and real time PCR assay with TaqMan probe. J Med Assoc Thai 2005, 88:S206-S213.
92. Rekhviashvili N, Stevens G, Scott L, Stevens W. Fluorogenic LUX primer for quantitation of HIV-1 by real-time RT-PCR. Mol Biotechnol 2006, 32:101-110.
93. Drosten C, Panning M, Drexler JF, Hansel F, Pedroso C, Yeats J, de Souza Luna LK, Samuel M, Liedigk B, Lippert U, et al. Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5′ long terminal repeat domain. Clin Chem 2006, 52:1258-1266.
94. Gueudin M, Plantier JC, Damond F, Roques P, Mauclere P, Simon F. Plasma viral RNA assay in HIV-1 group O infection by real-time PCR. J Virol Methods 2003, 113:43-49.
95. Damond F, Gueudin M, Pueyo S, Farfara I, Robertson DL, Descamps D, Chene G, Matheron S, Campa P, Hrun-Vezinet F, et al. Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections. J Clin Microbiol 2002, 40:3654-3659.
96. Lole KS, Arankalle VA. Quantitation of hepatitis B virus DNA by real-time PCR using internal amplification control and dual TaqMan MGB probes. J Virol Methods 2006, 135:83-90.
97. Dehee A, Cesaire R, Desire N, Lezin A, Bourdonne O, Bera O, Plumelle Y, Smadja D, Nicolas JC. Quantitation of HIV-1 proviral load by a TaqMan real-time PCR assay. J Virol Methods 2002, 102:37-51.
98. Leruez-Ville M, Ouachee M, Delarue R, Sauget AS, Blanche S, Buzyn A, Rouzioux C. Monitoring cytomegalovirus infection in adult and pediatric bone marrow transplant recipients by a real-time PCR assay performed with blood plasma.J Clin Microbiol 2003, 41:2040-2046.
99. Rouet F, Ekouevi DK, Inwoley A, Chaix M-L, Burgard M, Bequet L, Viho I, Leroy V, Simon F, Dabis F, et al. Field evaluation of a rapid human immunodeficiency virus (HIV) serial serologic testing algorithm for diagnosis and differentiation of HIV type 1 (HIV-1), HIV-2 and dual HIV-1-HIV-2 infections in West African pregnant women. J Clin Microbiol 2004, 42:4147-4153.
100. Holmes H, Davis G, Heath A, Hewlett I, Lelie N. An international collaborative study to establish the 1st international standard for HIV-1 RNA for use in nucleic acid-based techniques. J Virol Methods 2001, 92:141-150.
101. Tehe A, Maurice C, Hanson DL, Borget MY, Abiola N, Maran M, Yavo D, Tomasik Z, Boni J, Schupbach J, et al. Quantification of HIV-1 p24 by a highly improved ELISA: An alternative to HIV-1 RNA based treatment monitoring in patients from Abidjan, Côte d'Ivoire. J Clin Virol 2006 (in press).
102. Robertson DL, Anderson JP, Bradac JA, Carr JK., Foley B, Funkhouser RK, Gao F, Hahn BH, Kalish ML, Kuiken C, et al. HIV-1 nomenclature proposal. Science 2000, 288:55-56.
103. Peeters M, Sharp P. The genetic diversity of HIV-1: the moving target. AIDS 2000, 14:S129-S140.
104. Najera R, Delgado E, L PA, Thomson MM. Genetic recombination and its role in the development of the HIV-1 pandemic. AIDS 2002, 16:S3-S12.
105. Osmanov S, Pattou C, Walker N, Schwardlander B, Esparza J. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2002, 29:184-190.
106. Peeters M, Toure-Kane C, Nkengasong J. Genetic diversity of HIV in Africa: impact on diagnosis, vaccine development and trials. AIDS 2003, 17:2547-2560.
107. Tovanabutra S, Beyrer C, Sakkhachornphop S, Razak MH, Ramos GL, Vongchak T, Rungruengthanakit K, Saokhieo P, Tejafong K, Kim B, et al. The changing molecular epidemiology of HIV type I among northern Thai drug users, 1999 to 2002. AIDS Res Hum Retrovirus 2004, 20:465-475.
108. Russell KL, Carcamo C, Watts DM, Sanchez J, Gotuzzo E, Euler A, Blanco JC, Galeano A, Alava A, Mullins JI, et al. Emerging genetic diversity of HIV-1 in South America. AIDS 2000, 14:1785-1791.
109. Panakitsuwan S, Yoshihara N, Hashimoto N, Miyamura K, Chotpitayasunondh T. Early diagnosis of vertical HIV infection in infants by rapid detection of immune complex-dissociated HIV p24 antigen. Aids Patient Care and Stds 1997, 11:429-433.
110. Schupbach J. Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA. AIDS Rev 2002, 4:83-92.
111. Sherman GG, Stevens G, Stevens WS. Affordable diagnosis of human immunodeficiency virus infection in infants by p24 antigen detection. Pediatr Infect Dis J 2004, 23:173-176.
112. De Baets AJ, Edidi BS, Kasali MJ, Beelaert G, Schrooten W, Litzroth A, Kolsteren P, Denolf D, Fransen K. Pediatric human immunodeficiency virus screening in an African district hospital. Clin Diagn Lab Immunol 2005, 12:86-92.
113. Zijenah LS, Tobaiwa O, Rusakaniko S, Nathoo KJ, Nhembe M, Matibe P, Katzenstein DA. Signal-boosted qualitative ultrasensitive p24 antigen assay for diagnosis of subtype C HIV-1 infection in infants under the age of 2 years. J Acquir Immune Defic Syndr 2005, 39:391-394.
114. Rouet F, Montcho C, Rouzioux C, Leroy V. Msellati P, Kottan JB. You B, Viho I, Dabis F. Early diagnosis of paediatric HIV-1 infection among African breast-fed children using a quantitative plasma HIV RNA assay. AIDS 2001, 15:1849-1856.
115. Schupbach J, Gunthard H, Joos B, Fisher M, Boni J, Tomasik Z, Yerly S, Perrin L, Battegay M, Furrer H, et al. HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4+ T cell loss. J Acquir Immune Defic Syndr 2005, 40:250-256.
116. Cassol SA, Gill MJ, Pilon R, Cormier M, Voigt RF, Willoughby B, Forbes J. Quantification of human immunodeficiency virus type 1 RNA from dried plasma spots collected on filter paper. J Clin Microbiol 1997, 35:2795-2801.
117. Fiscus SA, Brambilla D, Grosso L, Schock J, Cronin M. Quantitation of human immunodeficiency virus type 1 RNA in plasma by using blood dried on filter paper. J Clin Microbiol 1998, 36:258-260.
118. Biggar RJ, Broadhead R, Janes M, Kumwenda N, Taha TET, Cassol S. Viral levels in newborn African infants undergoing primary HIV-1 infection. AIDS 2001, 15:1311-1313.
119. Brambilla D, Jennings C, Aldrovandi G, Bremer J, Comeau AM, Cassol SA, Dickover R, Jackson JB, Pitt J, Sullivan JL, et al. Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: Measurement, precision, and RNA stability. J Clin Microbiol 2003, 41:1888-1893.
120. Mwaba P, Cassol S, Nunn A, Pilon R, Chintu C, Janes M, Zumla A. Whole blood versus plasma spots for measurement of HIV-1 viral load in HIV-infected African patients. Lancet 2003, 362: 2067-2068.
121. Uttayamakul S, LikAnonsakul S, Sunthornkachit R, Kuntiranont K, Luoisirirotchankul S, Chaovavanich A, Thiamchai V, Tanprasertsuk S, Sutthent R. Usage of dried blood spots for molecular diagnosis and monitoring HIV-1 infection. J Virol Methods 2005, 128:128-134.
122. de Baar MP, Timmeremans EC, Buitelaar M, Westrop M, Dekker JT, Soerdjpal A, Kamping E, de Rooij E, Schuurman R. Evaluation of the HIV-1 RNA Retina™ Rainbow assay on plasma and dried plasma spots: correlation with the Roche Amplicor HIV-1 Monitor v 1.5 assay. Antiviral Therapy 2003, 8:S533.
123. Knuchel MC, Tomasik Z, Speck RF, Luthy R, Schupbach J. Ultrasensitive quantitative HIV-1 p24 antigen assay adapted to dried plasma spots to improve treatment monitoring in low-resource settings. J Clin Virol 2006, 36:64-67.
124. Plantier JC, Dachraoui R, Lemee V, Gueudin M, Borsa Lebas F, Caron F, Simon F. HIV-1 resistance genotyping on dried serum spots. AIDS 2005, 19:391-397.
125. Luo W, Yang H, Rathbun K, Pau CP, Ou CY. Detection of human immunodeficiency virus type 1 DNA in dried blood spots by a duplex real-time PCR assay. J Clin Microbiol 2005, 43: 1851-1857.
126. Uhlenhaut C, Kracht M. Viral infectivity is maintained by an RNA protection buffer. J Virol Methods 2005, 128:189-191.
127. Petti CA, Polage CR, Quinn TC, Ronald AR, Sande MA. Laboratory medicine in Africa: A barrier to effective health care. Clinical Infectious Diseases 2006, 42:377-382.
128. Fiscus SA, Cheng B, Crowe SM, Demeter L, Jennings C, Miller V, Respess R, Stevens W, and the Forum for Collaborative HIV Research Alternative Viral Load Assay Working Group. HIV-1 viral load assays for resource-limited settings. PLoS Med 2006, 3:e417-e424.
129. Calmy Alexandra, Ford N, Hirschel B, Reynolds SJ, Lynen L, Goemare E, Garcia de la Vega F, Perrin L, Rodriguez W. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007, 44:128-134.
130. Coloma J, Harris E. Innovative low cost technologies for biomedical research and diagnosis in developing countries. BMJ 2004, 329:1160-1162.